Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size


 
Table of Contents   
ORIGINAL ARTICLE
Year : 2021  |  Volume : 16  |  Issue : 2  |  Page : 172-177
Demographic and clinical patterns of severe asthma in the Middle East


1 Cleveland Clinic, Respiratory and Allergy Institute, Abu Dhabi, UAE
2 Department of Pulmonary Medicine, Rashid Hospital, Dubai, UAE
3 Division of Respiratory Medicine, Zayed Military Hospital, Abu Dhabi, UAE
4 Cleveland Clinic, Medical Sub-Specialties Institute, Abu Dhabi, UAE

Date of Submission06-Apr-2020
Date of Acceptance13-Oct-2020
Date of Web Publication17-Apr-2021

Correspondence Address:
Prof. Mohamed Abuzakouk
Respiratory Institute, Cleveland Clinic Abu Dhabi
UAE
Login to access the Email id


DOI: 10.4103/atm.ATM_131_20

Rights and Permissions

   Abstract 


BACKGROUND: Severe asthma is a major burden on health-economic resources; hence, knoing the epidemiology of these patients is important in planning and provision of asthma care. In addition, identifying and managing the comorbidities helps improve symptoms and reduce associated morbidity and mortality.
OBJECTIVES: Epidemiology of difficult asthma has not been ell studied in the Middle East, so in this study, e present the demographic and clinical characteristics of severe asthma in the United Arab Emirates (UAE).
METHODS: We retrospectively revieed the notes of severe asthma patients attending three tertiary care hospitals beteen May 2015 and December 2019. Data on baseline demographics, asthma characteristics, treatment, and comorbidities ere collected.
RESULTS: We revieed the notes of 458 patients (271 females and 187 males) that fulfilled the 2019 Global Initiative for Asthma guidelines for the diagnosis of severe asthma. The mean age as 47.7 (standard deviation 17.2) years. Males had significantly higher asthma control test scores (17.9 vs. 16, P = 0.01) and mean blood eosinophils (0.401 vs. 0.294, P <0.01) than females. The most common comorbidity observed as allergic rhinitis (52.2%) folloed by gastroesophageal reflux disease (27.1%). In total, 109 (23.8%) patients ere on biological therapies ith most patients being on omalizumab and dupilumab (29 and 18 patients, respectively). Most patients ere nonsmokers (97.2%), and majority ere of TH2-high phenotype (75.7%).
CONCLUSIONS: In this first report of severe asthma characteristics in the UAE, e found a pattern of female preponderance and most patients having a Th2-high phenotype. The findings are likely to help optimize asthma care in the region in the era of biologic therapies.


Keywords: Airflow obstruction, allergic asthma, asthma, asthma epidemiology, severe asthma epidemiology, Th1/Th2


How to cite this article:
Abuzakouk M, Ghorab OK, Mahboub B, Alzaabi A, Uzbeck MH, Nasir M, Zoumot Z, Grandon D, El Sameed YA, Namas R, Wahla AS, Chapman J, Saleh K, Salvo F, Bodi GS, Shafiq I. Demographic and clinical patterns of severe asthma in the Middle East. Ann Thorac Med 2021;16:172-7

How to cite this URL:
Abuzakouk M, Ghorab OK, Mahboub B, Alzaabi A, Uzbeck MH, Nasir M, Zoumot Z, Grandon D, El Sameed YA, Namas R, Wahla AS, Chapman J, Saleh K, Salvo F, Bodi GS, Shafiq I. Demographic and clinical patterns of severe asthma in the Middle East. Ann Thorac Med [serial online] 2021 [cited 2021 Jun 25];16:172-7. Available from: https://www.thoracicmedicine.org/text.asp?2021/16/2/172/313935




Asthma is a chronic lung disease characterized by airay inflammation and hyper-responsiveness affecting almost 300 million people orldide.[1] Asthma can be classified as mild, moderate, or severe, based on the intensity of treatment required to achieve asthma control.[2] Severe asthma is defined as asthma that requires treatment ith high-dose inhaled corticosteroids (ICS) to maintain good control or as asthma that is poorly controlled despite the use of maximal optimized therapy and treatment of contributory factors.[3] Severe asthma is reported to affect about 5%–10% of asthmatics.[2] It is important to differentiate severe asthma from difficult-to-treat asthma, hich is defined as asthma that is poorly controlled due to correctable factors such as environmental allergens, comorbidities, poor medication compliance, and incorrect inhaler technique.[3] While severe asthma is less prevalent than milder asthma severities, it remains a major cause of morbidity[4] and mortality[5],[6] orldide. In addition, it is associated ith a major socioeconomic,[7] psychological,[8] and treatment[9] burden.

The clinical characteristics and phenotypes of severe asthma patients have been previously reported from various parts of the orld,[10],[11],[12] and this knoledge has been particularly important for the development and application of novel biological therapies. In addition, severe asthma registries can be used for genetic profiling to help identify individuals ho are genetically predisposed to severe asthma. Difficult asthma phenotypes, including patients ith severe asthma, have not been ell studied in the Middle Eastern populations. The United Arab Emirates (UAE) has no official severe asthma registry and as yet no published data describing the characteristics of these patients. Undoubtedly, it is necessary to understand local epidemiology and clinical characteristics of severe asthma to make better-informed local guidelines and treatment decisions. Therefore, e took the initiative to examine the demographic and clinical variables of severe asthma in a local population attending three tertiary care hospitals in the UAE beteen May 2015 and December 2019.


   Methods Top


Subjects

We performed a retrospective chart revie of all patients diagnosed ith severe asthma according to the 2019 Global Initiative for Asthma (GINA) guidelines[3] attending Cleveland Clinic Abu Dhabi (Abu Dhabi), Rashid Hospital (Dubai), and Zayed Military Hospital (Abu Dhabi), beteen May 2015 and December 2019. Patients ere included if they had at least three visits to the asthma clinic, ith the visits being at least 1 month apart, ere on high-dose ICS ith optimal inhaler technique, shoed good compliance ith medication, and had good control of the contributing/exacerbating factors. Patients ith asthma-chronic obstructive pulmonary disease overlap syndrome and deceased patients ere excluded. We identified a total of 604 patients that met the inclusion/exclusion criteria, of hom 458 ere Emirati citizens and ere used to form the cohort for the current analysis.

Study variables

The medical records of all participants ere revieed by a study team comprised of one or to researchers at each study site. Apart from basic demographic information, the Asthma Control Test (ACT) scores, fractional exhaled nitric oxide (FeNO) levels, eosinophil counts, and total immunoglobulin E (IgE) levels ere also recorded. Comorbidities including body mass index, cigarette smoking, allergic rhinitis, hypertension, gastroesophageal reflux disease (GERD), hyperlipidemia, diabetes, obesity, obstructive sleep apnea (OSA), nasal polyps, thyroid disease, bronchiectasis, depression, anxiety, osteoporosis, food allergy, eczema, and malignancies ere documented.

Statistical analysis

Descriptive statistics ere used to summarize the characteristics of the cohort. Comparisons of categorical baseline characteristics in the cohort ere performed using Pearson's Chi-squared test. Comparisons of continuous baseline characteristics ere performed using Welch's to-sample t-test. We considered a p-value less than 0.05 to be statistically significant in our study.


   Results Top


Baseline characteristics

A total of 604 patients fulfilled the 2019 GINA guidelines for the diagnosis of severe asthma. Among these, 458 patients (75.8%) ere Emirati citizens, hereas 146 patients (24.2%) ere expatriates. Since our objective is to study the demographics of the local Arab population, the expatriates ere excluded from the analysis. Among the 458 patients, there ere 271 females (59.2%) and 187 males (41%) [Table 1]. The mean ± standard deviation age for females as higher than that for males (50.2 ± 16.6 years vs. 44.2 ± 17.4 years, P = 0.002), ith a range beteen 14 and 92 years.
Table 1: Comparison of severe asthma characteristics between different studies

Click here to view


Age of asthma onset as available for 241 patients, of these 111 patients (46.1%) reported having been diagnosed ith asthma in childhood, hereas 130 patients (53.9%) ere diagnosed as adults.

Information about asthma phenotype, i.e., allergic versus nonallergic as available for 242 patients. Out of those, 148 patients (61.2%) ere labeled as having allergic asthma and 35 patients (14.5%) suffered from eosinophilic asthma. Together these to groups made up the Th2 high phenotype (75.7%). The rest of the patients in the cohort (24.3%) ere nonallergic/Th2 lo phenotype.

We carried out statistical comparisons of asthma characteristics beteen males and females and identified significant differences in ACT scores and mean blood eosinophil count [Table 2]. A significantly higher mean ACT score and eosinophil count as observed in males compared to females (17.9 vs. 16, P = 0.01) and (0.401 vs. 0.294, P < 0.01), respectively. The mean IgE and FeNO levels ere not significantly different across genders.
Table 2: Comparison of asthma characteristics between males and females

Click here to view


Comorbidities and modifiable risk factors

The most frequent comorbidity observed as allergic rhinitis (52.2%), folloed by GERD (27.1%), hypertension (26.9%), hyperlipidemia (26.0%), diabetes (25.3%), obesity (20.3%), OSA (14.0%), nasal polyps (11.1%), thyroid disease (9.6%), bronchiectasis (5.5%), eczema (3.9%), food allergy (3.7%), depression (3.5%), anxiety (3.5%), and osteoporosis (3.1%). Sixty-to patients (13%) had a history of past/present smoking. We analyzed the difference beteen genders in terms of comorbidities and found that GERD and depression ere significantly more common in females hile nasal polyps and eczema ere more prevalent among males [Table 3].
Table 3: Comorbidities according to gender

Click here to view


Biological therapy

A total of 109 (23.8%) patients ere receiving biological therapy for the treatment of severe asthma. The breakdon of the data according to the biological agents shoed 56 (51.4%) patients on omalizumab, 29 (26.6%) patients on dupilumab, 18 (16.5%) patients on benralizumab, and 6 (5.5%) patients on mepolizumab.

Malignancy

Thirteen patients (2.8%) had a history of malignancy; the most common malignancies ere breast, lung, and thyroid cancer, each found in three patients. Colon cancer as found in to patients, and bladder cancer and prostate cancer ere each found in one patient.


   Discussion Top


The scarcity of data on severe asthma not only in the UAE, but also in the Middle East as a hole necessitated this retrospective revie in hich e evaluated the demographic and clinical characteristics of patients ith severe asthma in the UAE's local Arab population and compared our data ith previously published international cohorts. One of the earliest reports of asthma prevalence in the UAE stated that asthma affects about 13.6% of children in the UAE.[14] Hoever, there is a variation in the asthma prevalence rates recently reported in the UAE; one report suggested that asthma affects at least 9.8% of the total UAE population,[15] another report estimated that it affects 13% of the population[16] and a third report estimated that asthma affects 4.9% of the population.[2] The variation in prevalence rates may be due to the different methodologies used in each of the studies, here asthma definitions have differed from one study to another. With this in mind, it is sensible for us to estimate the asthma prevalence in that the UAE is about 8%–9%, similar to that found in Kuait (9.5%) and Saudi Arabia (8.3%).[2] The economic burden of asthma care in the emirate of Abu Dhabi as reported to be around 29 million USD in 2014;[17] hoever, ith increasing use of biologics in the severe asthma subgroup, this cost is likely to increase significantly.

The mean age of our severe asthma cohort as 47.7 ± 17.2, hich is loer than the three studies e used for comparison [Table 1]. Hoever, data from the Severe Asthma Research Program (SARP) registry[18] reported a mean age of 37 years hich is considerably loer than our cohort. This heterogeneity in the age of difficult asthma is interesting, being as high as 62.3 in Korea as reported by Kim et al.[10] and as lo as 37 in SARP, and it highlights that the care needs for these patient populations may be significantly different in the different parts of the orld.

In our study, almost 54% of the patients had adult onset asthma. It has been reported that age of onset affects the response of severe asthma patients to biological therapy. Patients ith adult onset usually respond better to anti-interleukin 5 (IL-5) or anti IL-5 receptor therapy, hereas patients ith childhood onset disease respond better to anti-IgE therapy.[3],[19] Our cohort as the youngest cohort compared to cohorts from other global studies, and therefore, this could explain hy more than half (51.4%) of our patients receiving biological therapy for severe asthma ere on anti-IgE therapy (Omalizumab).

We observed a female predominance of 59% in our patient cohort hich as no different from the studies e used for comparison. Although our observation is for severe asthma, it is ell-knon that females dominate all asthma severity groups. It has been suggested that sex hormones in females contribute to orse asthma symptoms compared to males, and animal studies have shon that oestrogen increased Th2-mediated airay inflammation, hile androgens reduced it.[20],[21] This is a significant finding as it not only provides an explanation for the difference in asthma prevalence, onset, and severity beteen males and females, but also offers opportunities for further studies to be carried out to assess the difference in inflammatory pathays beteen males and females and potentially consider hormonal therapy for asthma.

In this study, e found that males had significantly higher mean blood eosinophil count and ACT scores than females (P < 0.01 and P = 0.01, respectively); this is in concordance ith the previously reported data.[18],[22] This is an interesting observation firstly as previous studies have reported no gender-based differences in asthma control,[23] and secondly because females in our cohort ere older and more obese, hich are parameters associated ith orse asthma control.[24],[25]

Allergic rhinitis as the most prevalent comorbidity in our cohort (52.2%) as observed in other severe asthma cohorts.[10],[13] Allergic rhinitis is ell knon to coexist ith asthma and according to some authors more than 80% of asthmatics have a diagnosis of allergic rhinitis.[26] In addition, the presence of allergic rhinitis is thought to be associated ith increased asthma severity.[27],[28] This connection beteen allergic rhinitis and asthma is not surprising as the “united airay disease” theory suggests that the upper and the loer airay are functionally a singular unit and the inflammatory/allergic disorders in one are bound to have similar effects on the other.[29],[30] Hence, it is not surprising that treatment of allergic rhinitis ith nasal corticosteroids and the leukotriene receptor antagonists also seems to reduce asthma exacerbations and asthma-related respiratory symptoms.[31],[32]

Similar to other cohorts,[10],[12] GERD as the second most common co-morbidity observed in our patients (27.1%), and it is knon to be more prevalent among asthmatics compared to the general population.[33] We also observed a statistically significant difference in the prevalence of GERD beteen females and males (68.5% vs. 31.5%, respectively, P = 0.013). This finding has been reported in to other studies previously[34],[35] and is possibly due to the effect of estrogen on the loer esophageal sphincter; hoever, the mechanism is not entirely clear.

Anxiety and depression ere each present in 3.5% of the patients. Previously, Kim et al. had reported a somehat similar prevalence of anxiety and depression in their study hich as 1.7% and 3.7%, respectively.[10] We also observed a significant difference in the prevalence of depression beteen males and females ith a female preponderance (females 87.5%, males 12.5%, P = 0.02) hich is in accordance ith a higher prevalence of depression in omen in the general population.[36]

These findings are important as depression is reported to be a risk factor for developing asthma,[37] and both anxiety and depression are associated ith poor asthma control.[38]

The prevalence of nasal polyposis in the Middle East including the UAE has not been previously reported. In our patient population, nasal polyposis as present in 11.1% of the total cohort hile Wang et al. reported the prevalence of nasal polyposis to be 7.3%.[13] Nasal polyposis has been reported to be associated ith greater asthma severity;[39] hoever, e did not observe a significant difference in ACT scores beteen asthma patients ith and ithout nasal polyps (P = 0.5). Interestingly, e observed a significant difference in the prevalence of nasal polyposis beteen males and females (P = 0.013), here males had a higher prevalence (56.9% vs. 43.1%, P = 0.013) hich is in concordance ith previously reported data.[40]

The choice of biologics for the treatment of asthma is expanding and phenotyping difficult asthma is the necessary first step in deciding the need and the choice of biologic therapy. Omalizumab is an anti-IgE monoclonal antibody that is approved by the Food and Drug Agency (FDA) in the treatment of moderate-to-severe allergic asthma.[41] Mepolizumab (anti-IL5), Benralizumab (anti-IL5R), and Dupilumab (anti-IL4) are FDA approved for the treatment of severe eosinophilic asthma.[42],[43] Allergic asthma is ell knon to be the most common asthma phenotype orldide,[42] and in our cohort as ell, asthma as predominantly allergic (61.2%). Wang et al. suggested that early onset asthma combined ith high IgE levels predisposes patients to develop allergic asthma later on.[13] Our cohort had the higher mean blood IgE levels than the compared studies [Table 1], and almost 50% of the patients ere diagnosed ith asthma during childhood, therefore, our findings support this suggestion by Wang et al. On the other hand, nonallergic asthma is suggested to be defined by late disease onset combined ith loer IgE levels, as seen in one study.[43] The patients ho ere identified as having nonallergic asthma in our study ere predominantly diagnosed in adulthood and had a loer mean blood IgE compared to patients ith allergic asthma; hoever, the difference in mean blood IgE levels as not statistically significant.

Our study is focused on the Emirati population and completely excludes the expatriate population. The genetic makeup of Emiratis could be different to the expatriate population, hich ould reflect on the prevalence of the different severe asthma phenotypes. The UAE government provides its citizens ith a good quality health-care system administered by its Federal Ministry of Health, and this may explain the lo prevalence of severe asthma in the country. In addition, hile our study measures the prevalence of severe asthma across three major health-care centers in the UAE, the figure e report is not conclusive, as there may be patients receiving asthma care elsehere in the country. Moreover, data on the prevalence of comorbidities among UAE nationals is not available; therefore, e ere not able to determine hether the comorbidities e identified ere truly raised in the Emirati population ith severe asthma.


   Conclusion Top


In summary, our study is the first to report the demographics, clinical phenotypes and treatment variables in a large cohort of Emirati patients diagnosed ith severe asthma. Our findings provide important information regarding the understanding of the disease in the region and highlight the need for establishing a national registry to identify the true prevalence and help improve the management of severe asthma in the UAE.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr 2019;7:246  Back to cited text no. 1
    
2.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73  Back to cited text no. 2
    
3.
GINA-2019-main-Pocket-Guide-ms.pdf. Available from: https://ginasthma.org/p-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-ms.pdf. [Last accessed on 2020 Mar 15]  Back to cited text no. 3
    
4.
Nordon C, Grimaldi-Bensouda L, Pribil C, Nachbaur G, Amzal B, Thabut G, et al. Clinical and economic burden of severe asthma: A French cohort study. Respir Med 2018;144:42-9  Back to cited text no. 4
    
5.
Gupta RP, Mukherjee M, Sheikh A, Strachan DP. Persistent variations in national asthma mortality, hospital admissions and prevalence by socioeconomic status and region in England. Thorax 2018;73:706-12  Back to cited text no. 5
    
6.
Majeed H, Moore GWK. Influence of the Scandinavian climate pattern on the UK asthma mortality: A time series and geospatial study. BMJ Open 2018;8:e020822  Back to cited text no. 6
    
7.
Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116-24  Back to cited text no. 7
    
8.
Foster JM, McDonald VM, Guo M, Reddel HK. 'I have lost in every facet of my life': The hidden burden of severe asthma. Eur Respir J. 2017;50:1700765  Back to cited text no. 8
    
9.
Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: A focused revie of the impact data in the literature. Eur Respir J 2018;52:1800703  Back to cited text no. 9
    
10.
Kim MH, Kim SH, Park SY, Ban GY, Kim JH, Jung JW, et al. Characteristics of adult severe refractory asthma in Korea analyzed from the severe asthma registry. Allergy Asthma Immunol Res 2019;11:43-54  Back to cited text no. 10
    
11.
Gibson PG, McDonald VM. Management of severe asthma: Targeting the airays, comorbidities and risk factors. Intern Med J 2017;47:623-31  Back to cited text no. 11
    
12.
Novelli F, Bacci E, Latorre M, Seccia V, Bartoli ML, Cianchetti S, et al. Comorbidities are associated ith different features of severe asthma. Clin Mol Allergy 2018;16:25  Back to cited text no. 12
    
13.
Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Go AN, et al. Characterization of severe asthma orldide: Data from the international severe asthma registry. Chest 2020;157:790-804  Back to cited text no. 13
    
14.
Bener A, Abdulrazzaq YM, Debuse P, al-Mutaa J. Prevalence of asthma among Emirates school children. Eur J Epidemiol 1994;10:271-8  Back to cited text no. 14
    
15.
Mahboub BH, Al-Hammadi S, Rafique M, Sulaiman N, Paankar R, Al Redha AI, et al. Population prevalence of asthma and its determinants based on European Community Respiratory Health Survey in the United Arab Emirates. BMC Pulm Med 2012;12:4  Back to cited text no. 15
    
16.
Alsoaidi S, Abdulle A, Bernsen R. Prevalence and risk factors of asthma among adolescents and their parents in Al-Ain (United Arab Emirates). Respiration 2010;79:105-11  Back to cited text no. 16
    
17.
Alzaabi A, Alseiari M, Mahboub B. Economic burden of asthma in Abu Dhabi: A retrospective study. Clinicoecon Outcomes Res 2014;6:445-50  Back to cited text no. 17
    
18.
Cunningham AS. Eosinophil counts: Age and sex differences. J Pediatr 1975;87:426-7  Back to cited text no. 18
    
19.
Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Go A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 2018;52: 1800936  Back to cited text no. 19
    
20.
Fuseini H, Necomb DC. Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep 2017;17:19  Back to cited text no. 20
    
21.
Shah R, Necomb DC. Sex bias in asthma prevalence and pathogenesis. Front Immunol 2018;9:2997  Back to cited text no. 21
    
22.
Bittner JJ, Halberg F, Hamerston O. Sex difference in eosinophil counts in tall blood of mature B1 mice. Science 1957;125:73  Back to cited text no. 22
    
23.
Dursun AB, Kurt OK, Bayiz H, Ozkan E, Cakaloglu A, Karasoy D. Does gender affect asthma control in adult asthmatics? Chron Respir Dis 2014;11:83-7  Back to cited text no. 23
    
24.
Novosad S, Khan S, Wolfe B, Khan A. Role of obesity in asthma control, the obesity-asthma phenotype. J Allergy (Cairo) 2013;2013:538642  Back to cited text no. 24
    
25.
Gosavi S, Nadig P, Haran A. Factors contributing toards poor asthma control in patients on regular medication. J Clin Diagn Res 2016;10:OC31-5  Back to cited text no. 25
    
26.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration ith the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008;63 Suppl 86:8-160  Back to cited text no. 26
    
27.
Thomas M. Allergic rhinitis: Evidence for impact on asthma. BMC Pulm Med 2006;6 Suppl 1:S4  Back to cited text no. 27
    
28.
Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG. Allergic rhinitis and sinusitis in asthma: Differential effects on symptoms and pulmonary function. Chest 2006;130:429-35  Back to cited text no. 28
    
29.
Grossman J. One airay, one disease. Chest 1997;111:11S-16S  Back to cited text no. 29
    
30.
Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airay disease: Current perspectives. J Asthma Allergy 2016;9:93-100  Back to cited text no. 30
    
31.
Crystal-Peters J, Neslusan C, Cron WH, Torres A. Treating allergic rhinitis in patients ith comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57-62  Back to cited text no. 31
    
32.
Busse WW, Casale TB, Dykeicz MS, Meltzer EO, Bird SR, Hustad CM, et al. Efficacy of montelukast during the allergy season in patients ith chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96:60-8  Back to cited text no. 32
    
33.
Ates F, Vaezi MF. Insight into the relationship beteen gastroesophageal reflux disease and asthma. Gastroenterol Hepatol (N Y) 2014;10:729-36  Back to cited text no. 33
    
34.
Fakhre Yaseri H. Gender is a risk factor in patients ith gastroesophageal reflux disease. Med J Islam Repub Iran 2017;31:58  Back to cited text no. 34
    
35.
Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil 2016;22:575-88  Back to cited text no. 35
    
36.
Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004;164:1010-4  Back to cited text no. 36
    
37.
Gao YH, Zhao HS, Zhang FR, Gao Y, Shen P, Chen RC, et al. The Relationship beteen Depression and Asthma: A Meta-Analysis of Prospective Studies. PLoS One 2015;10:e0132424  Back to cited text no. 37
    
38.
Amelink M, Hashimoto S, Spinhoven P, Pasma HR, Sterk PJ, Bel EH, et al. Anxiety, depression and personality traits in severe, prednisone-dependent asthma. Respir Med 2014;108:438-44  Back to cited text no. 38
    
39.
Salvin RG, Cannon RE, Friedman WH, Palitang E, Sundaram M. Sinusitis and bronchial asthma. J Allergy Clin Immunol 1980;66:250-7  Back to cited text no. 39
    
40.
Meymane Jahromi A, Shahabi Pour A. The Epidemiological and Clinical Aspects of Nasal Polyps that Require Surgery. Iran J Otorhinolaryngol 2012;24:75-8  Back to cited text no. 40
    
41.
FDA. Omalizumab Precribing Information. Available from: https://.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf. [Last accessed on 2020 Mar 15]  Back to cited text no. 41
    
42.
Arbes SJ Jr., Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007;120:1139-45  Back to cited text no. 42
    
43.
Jones TL, Neville DM, Chauhan AJ. Diagnosis and treatment of severe asthma: A phenotype-based approach. Clin Med (Lond) 2018;18:s36-40.  Back to cited text no. 43
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
Print this article  Email this article
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (528 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Methods
   Results
   Discussion
   Conclusion
    References
    Article Tables

 Article Access Statistics
    Viewed474    
    Printed4    
    Emailed0    
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal